↑ Rising
Business
🔮 holds
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
Biotech
11 independently sourced, verified trend briefs about this subject.
What this topic page includes
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jun 29, 2026 through Aug 18, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
◼ Archived
Business
🔮 holds ✗
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
◼ Archived
Business
🔮 fades ✗
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares slide despite second-quarter earnings and revenue beats, driven by softness in its biotech unit.
◼ Archived
Business
🔮 fades ✓
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
◼ Archived
Business
🔮 holds ✓
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Researchers and investors are evaluating new clinical data from Biogen as the firm explores tau-targeting treatments for Alzheimer’s disease.
◼ Archived
Business
🔮 holds ✓
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.
◼ Archived
Business
🔮 fades ✓
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
◼ Archived
Health
🔮 holds ✗
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from initial human trials.
◼ Archived
Business
🔮 holds ✗
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its cancer-drug pipeline through the acquisition of U.K.-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.
◼ Archived
Business
🔮 holds ✗
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
◼ Archived
Business
🔮 fades ✓
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.